Pulmonary Adenocarcinoma of Low Malignant Potential

Principal Investigator

Name
Eric Burks

Degrees
MD

Institution
Boston University School Of Medicine

Position Title
Associate Professor

Email
eric.burks@bmc.org

About this CDAS Project

Study
NLST (Learn more about this study)

Project ID
NLST-867

Initial CDAS Request Approval
Jan 7, 2022

Title
Pulmonary Adenocarcinoma of Low Malignant Potential

Summary
Overdiagnosis in the CTLS arm of the NLST was associated with bronchoalveolar carcinoma (BAC). There was no central pathologic review for the NLST and BAC represented an entity whose criteria had been multiply revised and inconsistently applied before ultimately being abandoned by the IASLC and WHO after the NLST publication. More recently, my group has defined histologic criteria associated with indolent lung adenocarcinoma behavior after complete resection. This entity is termed "pulmonary adenocarcinoma of low malignant potential" and in combination with adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) corresponded to a frequency similar to that of BAC among stage I adenocarcinoma in the CTLS arm of the NLST.

Yambayev I, Sullivan TB, Suzuki K, Zhao Q, Higgins SE, Yilmaz OH, Litle VR, Moreira P, Servais EL, Stock CT, Quadri SM, Williamson C, Rieger-Christ KM, Burks EJ. Pulmonary Adenocarcinomas of Low Malignant Potential: Proposed Criteria to Expand the Spectrum Beyond Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma. Am J Surg Pathol. 2021 Apr 1;45(4):567-576. PubMed PMID: 33177339.

Aims

-Assess the frequency of LMP among CTLS and CXR detected cohorts of resected lung cancer
-Confirm the indolent nature of LMP in these cohorts compared to non-LMP adenocarcinoma and squamous cell carcinoma
-Determine if LMP correlates with overdiagnosis as did the historic entity BAC.

Collaborators

Kimberly Rieger-Christ, Ph.D.
Travis Sullivan, M.S.
Lahey Hospital and Medical Center